A Phase IB Study of Mosunetuzumab in People with Recurrent or Persistent Chronic Lymphocytic Leukemia

Share

Full Title

A Phase Ib Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

Purpose

The purpose of this study is to assess the safety of the investigational drug mosunetuzumab in people with chronic lymphocytic leukemia (CLL) that has come back or continued to grow despite treatment. It targets two types of immune cells: T cells and B cells. Mosunetuzumab helps the immune system attack cancer by directing T cells to kill cancerous B cells. It is given as a subcutaneous (under the skin) injection.

Eligibility

To be eligible for this study, patients must meet several requirements, including:

  • Participants must have CLL that has come back or continued to grow despite at least two prior regimens of therapy that included a BTK inhibitor (such as ibrutinib) and/or venetoclax.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for people age 18 and older.

For more information and to ask about eligibility for this study, please contact the office of Dr. Anthony Mato at 646-608-3748.

Protocol

22-119

Phase

I

Disease Status

Relapsed or Refractory

Investigator

Co-Investigators